An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
Related Posts
The Risky Strategy Behind Nike's Massive Holiday Discounts
December 22, 2024
10:32 am
Horvat, Islanders down Matthews-less Maple Leafs | Globalnews.ca
December 22, 2024
6:24 am
The long trend of falling corporate taxes is being reversed
December 22, 2024
5:12 am